Stefano Rivella, PhD Stefano Rivella, PhD, is a research faculty member in the Division of Hematology at The Children's Hospital of Phil adelphia. Locations: Main Campus Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467) Education and Training FellowshipPost-Doctoral Fellow, Memorial Sloan Kettering Cancer Center, New York, NY Graduate DegreePhD - University of Pavia, Pavia, Italy Titles and Academic Titles Professor of PediatricsProfessor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania Departments and Services Division of Hematology Publications Papers2016 Casu C, Oikonomidou PR, Chen H, Nandi V, Ginzburg Y, Prasad P, Fleming RE, Shah YM, Valore EV, Nemeth E, Ganz T, MacDonald B, Rivella S.: Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. Blood. 2016 May 6. pii: blood-2015-10-676742. Oikonomidou PR, Casu C, Yang Z, Crielaard B, Shim JH, Rivella S, Vogiatzi MG.: Polycythemia is associated with bone loss and reduced osteoblast activity in mice. Osteoporos Int. 2016 Apr;27(4):1559-68. Casu C, Aghajan M, Oikonomidou PR, Guo S, Monia BP, Rivella S. Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica. 2016 Jan;101(1):e8-e11. doi: 10.3324/haematol.2015.133348. Epub 2015 Sep 24. Chen H, Choesang T, Li H, Sun S, Pham P, Bao W, Feola M, Westerman M, Li G, Follenzi A, Blanc L,Rivella S, Fleming R, Ginzburg Y.: Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation. Haematologica. 2016 Mar;101(3):297-308. 2015 Valdés-Ferrer SI, Papoin J, Dancho ME, Olofsson P, Li J, Lipton JM, Avancena P, Yang H, Zou YR, Chavan SS, Volpe BT, Gardenghi S, Rivella S, Diamond B, Andersson U, Steinberg BM, Blanc L, Tracey KJ.: HMGB1 mediates anemia of inflammation in murine sepsis survivors. Mol Med. 2015 Dec 29. Das N, Xie L, Ramakrishnan SK, Campbell A, Rivella S, Shah YM.: Intestine-specific Disruption of Hypoxia-inducible Factor (HIF)-2α Improves Anemia in Sickle Cell Disease. J Biol Chem. 2015 Sep 25;290(39):23523-7. Breveglieri G, Mancini I, Bianchi N, Lampronti I, Salvatori F, Fabbri E, Zuccato C, Cosenza LC, Montagner G, Borgatti M, Altruda F, Fagoonee S, Carandina G, Rubini M, Aiello V, Breda L, Rivella S, Gambari R: Generation and characterization of a transgenic mouse carrying a functional human beta-globin gene with the IVSI-6 thalassemia mutation. BioMed Research International Biomed Res Int. 2015;2015:687635 Yien Yvette Y, Gnanapragasam Merlin Nithya, Gupta Ritama, Rivella Stefano, Bieker James J: Alternative splicing of EKLF/KLF1 in murine primary erythroid tissues. Experimental hematology 43(1): 65-70, Jan 2015. 2014 Zhang Xin, Campreciós Genís, Rimmelé Pauline, Liang Raymond, Yalcin Safak, Mungamuri Sathish Kumar, Barminko Jeffrey, D'Escamard Valentina, Baron Margaret H, Brugnara Carlo, Papatsenko Dmitri, Rivella Stefano, Ghaffari Saghi: FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. American journal of hematology 89(10): 954-63, Oct 2014. Guimarães Jacqueline S, Cominal Juçara G, Silva-Pinto Ana Cristina, Olbina Gordana, Ginzburg Yelena Z, Nandi Vijay, Westerman Mark, Rivella Stefano, de Souza Ana Maria: Altered erythropoiesis and iron metabolism in carriers of thalassemia. European journal of haematology Oct 2014. Deng Wulan, Rupon Jeremy W, Krivega Ivan, Breda Laura, Motta Irene, Jahn Kristen S, Reik Andreas, Gregory Philip D, Rivella Stefano, Dean Ann, Blobel Gerd A: Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell 158(4): 849-60, Aug 2014. Kautz Léon, Jung Grace, Valore Erika V, Rivella Stefano, Nemeth Elizabeta, Ganz Tomas: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature genetics 46(7): 678-84, Jul 2014. Kautz Léon, Jung Grace, Valore Erika V, Rivella Stefano, Nemeth Elizabeta, Ganz Tomas: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature genetics 46(7): 678-84, Jul 2014. Martin Leenus, Grigoryan Arsen, Wang Ding, Wang Jinhua, Breda Laura, Rivella Stefano, Cardozo Timothy, Gardner Lawrence B: Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations. Cancer research 74(11): 3104-13, Jun 2014. Coe Lindsay M, Madathil Sangeetha Vadakke, Casu Carla, Lanske Beate, Rivella Stefano, Sitara Despina: FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. The Journal of biological chemistry 289(14): 9795-810, Apr 2014. BooksChapters 2014 Crielaard BJ and Rivella S: Disorders of iron metabolism: iron deficiency and iron overload and anemia of chronic diseases in Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms; Elsevier 2014. Breda Laura, Rivella Stefano: Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. Hematology/oncology clinics of North America 28(2): 375-86, Apr 2014. 2013 Dong A and Rivella S: Gene addition strategies for the beta-thalassemias and SCD in Gene and Cell Therapies for Beta-Globinopathies. Editors Drs. Punam Malik MD, and John Tisdale, PhD; Springer Science 2013 Apr;161(4):293-306. 2012 Rivella S, Giardina JP: Thalassemia Syndromes. 6th Edition of Hematology: Basic Principles and Practice, Elsevier 2012. Rivella S: Disorders of red cell production and the iron-loading anemias in Iron Physiology and Pathophysiology in Humans. Editors: Anderson JG and McLaren GD. Humana Press 2012. Gardenghi S, Rivella S: New insight on the management of ineffective erythropoiesis and iron overload in ß-thalassemia and related hemoglobinopathies. Book of the European Hematology Association (EHA). 2012. 1994 Tribioli C, Maestrini E, Bione S, Tamanini F, Mancini M, Sala C, Torri G, Rivella S, Toniolo D: Identification of genes and construction of a transcriptional map in Xq28. Identification of Transcribed Sequences-Plenum Press 1994. Posters and PresentationsLectures by Invitation 2015 Rivella S. Novel approaches to treat disorders of red cell production [lecture]. NIH-NHLBI; 2015 Dec; Washington, DC. Rivella S. First Annual Toshia Asakura Lecture: Sickle Cell Disease: From Disease Discovery to Gene Therapy [lecture]. Children Hospital of Philadelphia (CHOP); 2015 Nov; Philadelphia, PA. Rivella S. Novel Therapies for Hemoglobinopathies [lecture]. Rana therapeutics; 2015 Nov; Boston, MA. Rivella S. Novel Therapeutic Approaches for Hemoglobinopathies [lecture]. American University of Lebanon; 2015 Nov; Beirut, Lebanon. Rivella S. Novel therapeutic approaches for disorders of aberrant erythropoiesis, iron metabolism and inflammation [lecture]. CHOP, Hematology; 2015 Oct; Philadelphia, PA. Rivella S. Session Emerging Therapies: Using Murine Thalassemia Models to Evaluate Novel Therapies [lecture]. 10th Cooley’s Anemia Foundation Meeting; 2015 Oct; Chicago, IL. Rivella S. New Therapeutic approaches to Thalassemia excluding gene therapy, in Red Cell Biology Thirty Years After. [lecture] Dipartimento di Scienze Cliniche e di Comunità, Università degli studi di Milano, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico; 2015 Sep; Milan, Italy. Rivella S. A double knock out of Hepcidin and Il6 demonstrates independent roles of the two genes in anemia of inflammation [lecture]. Bioiron, Zhejiang University; 2015 Sep; Hangzhou, China. Rivella S. Lack of beta-1 integrin limits stress erythropoiesis and splenomegaly in beta-thalassemia [lecture]. Bioiron, Zhejiang University; 2015 Sep; Hangzhou, China. Rivella S. Exploiting hepcidin and its pathway to limit iron absorption and erythroid iron intake [lecture]. Bioiron, Zhejiang University; 2015 Sep; Hangzhou, China. Rivella S. Genetic treatment of hemoglobinopathies [lecture]. Kadmon Pharmaceuticals; 2015 Sep; New York, NY. Rivella S. Addressing unmet therapeutic goals in patients with thalassemia: what does the future hold? [lecture] Novartis Advisory Board on Hemoglobinopathies; 2015 Jul; Barcelona, Spain. Rivella S. Forced chromatin looping increases fetal globin expression to curative levels in sickle cell anemia [lecture]. Gordon Conference on Red cells; 2015 Jun; Holderness, NH. Rivella S. Genome editing for disease correction [lecture]. Sickle Cell in Focus (SCiF); 2015 Jun; London, UK. Rivella S. Combination of gene transfer and forced chromatin looping concurrently decreases sickle cell hemoglobin and reactivates the synthesis of fetal hemoglobin in patient cells [lecture]. Plenary Session, Presidential Symposium, European Hematology Association (EHA); 2015 Jun; Vienna, Austria. Rivella S. The heme and iron connection: From Disease Models Of Abnormal Iron Metabolism And Erythropoiesis To Novel Therapies [lecture]. European Hematology Association (EHA); 2015 Jun; Vienna, Austria. Rivella S. Ironing and looping erythropoiesis: new potential therapeutics for old diseases [lecture]. University of Milan; 2015 May; Milan, Italy. Rivella S. New therapies for the treatment of hemoglobinopathies: from modulating iron metabolism to gene therapy [lecture]. Graduate Program in Areas of Basic and Applied Biology (GABBA); 2015 May; Porto, Portugal. Rivella S. How do JAK2 inhibitors and hepcidin mimetics modulate iron metabolism and ineffective erythropoiesis? [lecture] Berlin-Global Iron Summit; 2015 Mar; Berlin, Germany. 2014 Rivella S. Iron Age: Novel Targets for Iron Overload [lecture]. ASH; 2014 Dec; San Francisco, CA. Rivella S. The role of iron and macrophages in normal and aberrant erythropoiesis [lecture]. Weatherall Institute of Molecular Medicine; 2015 Nov; UK. Rivella S. Ironing and looping erythropoiesis: new potential therapeutics for old diseases [lecture]. NYU College of Dentistry; 2014 Nov; NY, NY. Rivella S. Ironing and looping erythropoiesis: new potential therapeutics for old diseases [lecture]. University of Massachusetts Medical School (UMMS); 2014 Nov; Worchester, MA. Rivella S. Ironing and looping erythropoiesis: new potential therapeutics for old diseases [lecture]. Professor Round's-Pediatrics Weill-Cornell Medical Center; 2014 Oct; New York, NY. Rivella S. The role of iron and macrophages in normal and aberrant erythropoiesis [lecture]. Columbia University, Department of Physiology; 2014 Oct; New York, NY. Rivella S. Gene Therapy for Sickle Cell Anemia [lecture]. New York Blood Center; 2014 Sep; New York, NY. Rivella S. Molecules at the crossroad between erythropoiesis and iron metabolism [lecture]. Bayer Pharmaceuticals; 2014 Sep; San Francisco, CA. Rivella S. Expectations, achievements and challenges of gene transfer for the cure of hemoglobinopathies [lecture]. 57th National Meeting of the Italian Society of Biochemistry and Molecular Biology; 2014 Sep; Ferrara, Italy. Rivella S. Gene therapy for hemoglobinopathies [lecture]. Division of Hematology, The Children's Hospital of Philadelphia; 2014 Jul; Philadelphia, PA. Rivella S. New potential therapeutics for hemoglobinopathies: from regulation of erythropoiesis to gene therapy [lecture]. San Raffaele Institute; 2014 Jun; Milan, Italy. Rivella S. New therapeutics for hemoglobinopathies [lecture]. Graduate Program in Areas of Basic and Applied Biology (GABBA); 2014 May; Porto, Portugal. Rivella S. The role of iron and macrophages in normal and aberrant erythropoiesis [lecture]. Division of Hematology; 2014 Apr; The Children's Hospital of Philadelphia; Philadelphia, PA. Rivella S. New potential therapeutic approaches for hemoglobinopathies [lecture]. Universita' degli Studi; 2014 Apr; Milan, Italy. Rivella S. Gene therapy for Hemoglobinopathies: Time for clinical trials? [lecture]. Sickle Cell Disease, European Hematology Association (EAH); 2014 Apr; Milan, Italy. Rivella S. New potential therapeutics for hemoglobinopathies: from regulation of erythropoiesis to gene therapy [lecture]. Imperial College; 2014 Mar; London, UK. Rivella S. New potential therapeutic approaches for hemoglobinopathies [lecture]. King's College; 2014 Mar; London, UK. Awards and Honors 2015, Sultan bin Khalifa International Thalassemia Award, Innovative Medical Research Award-Abu Dhabi, United Arab Emirates 2007, Travel Grant Award, International BioIron Society (IBIS) 2005, Travel Grant Award, International Society of Experimental Hematology (ISEH) 2004, Travel Grant Award, International Society of Experimental Hematology (ISEH) 2002, Travel Grant Award, American Society of Gene & Cell Therapy (ASGCT) 2002, The T. Ray Bradley First Prize for New Investigator Award, ISEH 2002, Travel Grant Award, International Society of Experimental Hematology (ISEH) 1997, Doctoral Award, Department of Genetics, University of Pavia, Italy 1994, Prize for the best poster, International Symposium on Genomic Imprinting and New Approaches in the Identification and Mapping of Genetic Syndromes, Florence, Italy 1991, Prize for the best poster, International Symposium on Genomic Imprinting and New Approaches in the Identification and Mapping of Genetic Syndromes, Florence, Italy Editorial and Academic Positions Editorial Positions 2015-present, Reviewer, Haematologica 2012-present, Ad Hoc Reviewer, Nature Science 2012-present, Ad Hoc Reviewer, Nature Medicine 2012-present, Ad Hoc Reviewer, Gene Therapy 2012-present, Ad Hoc Reviewer, JCI 2012-present, Ad Hoc Reviewer, Haematologica 2012-present, Ad Hoc Reviewer, PLOS ONE 2012-present, Ad Hoc Reviewer, Nature Communications 2008-present, Reviewer, Blood Academic and Institutional Committees 2014, Committee member, Vincent du Vigneaud Research Symposium 2012-present, Member of the committee to select candidates for the Tri-Institutional MD-PhD Program 2011-present, Committee for the recruitment and mentorship of PhD students applying to the combined-Weill Cornell Graduate School (WCGS) programs in Biochemistry & Structural-Biology, Cell & Developmental Biology, and Molecular Biology 2010-present, Committee for the recruitment and mentorship of pediatric hematology/oncology fellows applying to New York Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center joint fellowship program 2009-present, Teacher of the graduate program in areas of basic and applied biology (GABBA), Portugal Leadership and Memberships Memberships in Professional Organizations International 2014-2015, International Society for Stem Cell Research (ISSCR) (Member) 2013-present, International BioIron Society (IBIS) (Director) 2006-present, International BioIron Society (IBIS) (member) National 2014, NIH-NIDDK and NHLBI (National Institute of Diabetes and Digestive and Kidney Diseases and National Heart, Lung, and Blood Institute) - Molecular and Cellular Hematology study section, ad hoc member 2013-present, NIH-NIDDK KUH (Kidney-Urology-Hematology) - Fellowship Reviewer Panel, Permanent member 2012-2015, Committee on Hemoglobin and Red Cells, American Society of Hematology -2015, Chair - 2014, Vice-chair 2012-present, American Society of Hematology Committee on Iron and Heme 2006-present, American Society of Hematology (ASH) Patient Experience Ratings About the Patient Experience Rating System The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question. Responses are measured on a scale of 1 to 5 with 5 being the best score. We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments. Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care. The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.